Clinical Trials Logo

Clinical Trial Summary

A Phase IV, Randomised, Double-blind, Single-centre clinical trial in healthy male and female participants aged 18 to 55, that was designed to assess and compare the pain intensity at an injection site as well as the duration of pain following a single dose subcutaneous administration of two low molecular weight heparins (LMWH) respectively.


Clinical Trial Description

This was a Phase IV, Randomised, Double-blind, Single-centre clinical trial in healthy male and female participants aged 18 to 55, that was designed to assess and compare the pain intensity at an injection site as well as the duration of pain following a single dose subcutaneous administration of two LMWHs respectively. This study included an approximate seven-day screening period (screening visit to day 0), followed by three visits (Visit 2, 3 and 4) in one-week intervals, in which each participant should have received a single sequence of subcutaneous injections of Placebo, Fraxiparine and Clexane, in a randomised order, on the three separate occasions. This was then followed by a safety follow-up visit, one week after the administration of the last dose of the study product.

Fifteen (N = 15) healthy, consenting participants, fulfilling the inclusion criteria, were randomised to take part in this study. All participants received a single sequence of subcutaneous injections, on separate occasions at one week intervals, over the duration of the treatment phase of the study. Fifteen (N=15) participants received Fraxiparine, fifteen (N=15) participants received Clexane and fifteen (N=15) participants received Placebo. Two participants were screened however did not meet the eligibility criteria and therefore were not included into the study. Informed consent was obtained at Screening Visit 1 (day -7 to 0) before any trial-related procedures were be performed. Visual analogue and 11-point numeric rating scales were utilised to measure pain intensity after a single injection of investigational product. These scales were also used to assess burning and pruritus. All scales were be completed at set time intervals over a 30 minute period, i.e. 1, 3, 5, 10, 15 and 30 minutes after the injections were completed. Hematoma, erythema and oedema were measured minutes and 1, 2 and 3 days after the injection, using transparent millimetric measuring paper. Safety bloods were drawn at each visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03841396
Study type Interventional
Source Aspen Global Incorporated
Contact
Status Completed
Phase Phase 4
Start date June 2, 2016
Completion date July 15, 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06093815 - Prospective Study to Assess Tissue Responses After Injection With Biostimulatory Products N/A
Completed NCT05007041 - Simultaneous RZV and aIIV4 Vaccination Phase 4
Completed NCT05157230 - Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination N/A
Completed NCT05028361 - Simultaneous mRNA COVID-19 and IIV4 Vaccination Study Phase 4
Completed NCT03645369 - Effectiveness of Mechano-Analgesia and Cold Application on Ecchymosis, Pain and Satisfaction at Subcutaneous Heparin Injection N/A
Recruiting NCT04962152 - Naldebain and Video-assisted Thoracoscopic Surgery Phase 4
Completed NCT03183908 - FLUAD® vs. Fluzone® High-Dose Study Phase 4
Recruiting NCT05221333 - Sorrel 25R Injector - Sorrel Clinical Study Protocol N/A
Completed NCT05157191 - Safety of Pediatric COVID-19 Vaccination